Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 18/20 | 0.56 |
| ▸ | F11 | P03951 | 17/20 | 0.56 |
| ▸ | F10 | P00742 | 15/20 | 0.56 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.53 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.53 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.50 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.50 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028756 | 0.88 | F7 (0.50) | F7F11F10PRKAG1PRKAA1 | |
| SCHEMBL11022330 | 0.88 | F7 (0.49) | F7F11F10PRKAG1PRKAA1 | |
| SCHEMBL45587 | 0.87 | PRKAG1 (0.57) | F7F11F10PRKAG1PRKAA1 | |
| SCHEMBL15751961 | 0.86 | PRKAG1 (0.49) | F7F11F10PRKAG1PRKAA1 | |
| SCHEMBL44985 | 0.82 | PRKAG1 (0.53) | F7F11F10PRKAG1PRKAA1 | |
| SCHEMBL11026442 | 0.78 | PRKAG1 (0.52) | F7F11F10PRKAG1PRKAA1 | |
| SCHEMBL11024427 | 0.76 | PRKAG1 (0.50) | F7F11F10PRKAG1PRKAA1 | |
| SCHEMBL43486 | 0.73 | SLC6A12 (0.51) | — | |
| SCHEMBL3538346 | 0.72 | F11 (1.00) | F7F11F10 | |
| SCHEMBL2529433 | 0.72 | PRKAG1 (0.46) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588458-B1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | claimed |
| EP-2588458-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-08 | — | — | EP | claimed |
| WO-2012001020-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-05 | — | — | WO | claimed |
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2588458-B1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | disclosed |
| EP-2588458-B1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | disclosed |
| EP-2668165-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| US-8592594-B2 | Tetrahydro-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2588458-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012101068-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-01-05 | — | — | US | disclosed |
| WO-2012001020-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012001020-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | RAB1A, RABL3, RAB7A | F7 2297/4885F11 2989/4885F10 2432/4885 |
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | GPR119, PRKAB1, PRKAG1 | F7 4706/4885F11 4266/4885F10 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.